Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)-Reference-Cited by-同舟云学术

Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study)

Published:2024 Issue:6 Volume:71 Page:603-616
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Furusawa Sho¹^ORCID,Nomoto Hiroshi¹^ORCID,Oba-Yamamoto Chiho²,Takeuchi Jun²,Ito Miki³,Kurihara Hiroyoshi³,Aoki Shin⁴,Miya Aika¹,Kameda Hiraku¹,Nakamura Akinobu¹,Atsumi Tatsuya¹

Affiliation:

1. Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo 060-8638, Japan

2. Sapporo Diabetes and Thyroid Clinic, Sapporo 060-0807, Japan

3. Kurihara Clinic, Sapporo 004-0053, Japan

4. Aoki Clinic, Sapporo 003-0023, Japan

Publisher

Japan Endocrine Society

Link

https://www.jstage.jst.go.jp/article/endocrj/71/6/71_EJ23-0648/_pdf

Reference25 articles.

1. 1 Davis TM, Chubb SA, Bruce DG, Davis WA (2016) Metabolic memory and all-cause death in community-based patients with type 2 diabetes: the fremantle diabetes study. Diabetes Obes Metab 18: 598–606.

2. 2 Rubin RR, Peyrot M (1999) Quality of life and diabetes. Diabetes Metab Res Rev 15: 205–218.

3. 3 Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, et al. (2017) Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 5: 951–964.

4. 4 Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580–591.

5. 5 Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, et al. (2022) Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 45: 2753–2786.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semaglutide use in people with obesity and type 2 diabetes from real‐world utilization data: An analysis of the All of US Program;Diabetes, Obesity and Metabolism;2024-09-09

2. Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies;Trends in Endocrinology & Metabolism;2024-08

3. Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches;Journal of Pharmacy & Pharmaceutical Sciences;2024-06-06